<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-340 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-340</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-340</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-6.html">extraction-schema-6</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation prevalence in lung cancer across different ethnic populations, particularly comparing Asian and non-Asian populations, and any proposed explanations for ethnic differences.</div>
                <p><strong>Paper ID:</strong> paper-273401012</p>
                <p><strong>Paper Title:</strong> Targeting EGFR Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer: Changes in Treatment Strategies are Coming</p>
                <p><strong>Paper Abstract:</strong> Epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations are the third most frequent EGFR mutation type, following only exon 19 deletions and exon 21 L858R point mutations. EGFR ex20ins mutations are found in approximately 4%-12% of all EGFR-positive non-small cell lung cancers (NSCLCs). Unlike classical EGFR mutations, EGFR ex20ins mutations display remarkable subtype diversity and heterogeneity. Patients harboring these mutations generally have an inferior prognosis because of insensitivity to conventional treatment approaches such as immunotherapy, chemotherapy, and targeted therapy. Consequently, there remains a significant unmet medical need for efficacious treatments. Recently, amivantamab and sunvozertinib have demonstrated notable efficacy as first-line treatments, and several other promising novel targeted drugs are also challenging the status quo of traditional first-line platinum-based chemotherapy regimens. These developments are anticipated to further improve survival outcomes for NSCLC patients with EGFR ex20ins mutations. Hence, this review summarizes the epidemiology, molecular attributes, detection methodologies, and therapeutic advancements for EGFR ex20ins mutations in NSCLC, and briefly discusses the mechanisms of drug resistance.</p>
                <p><strong>Cost:</strong> 0.018</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e340.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e340.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation prevalence in lung cancer across different ethnic populations, particularly comparing Asian and non-Asian populations, and any proposed explanations for ethnic differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>EGFR prevalence by ethnicity</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Overall EGFR mutation prevalence in NSCLC by ethnicity (Asian vs Caucasian)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>The paper reports summary prevalence ranges for activating EGFR mutations in non-small cell lung cancer, contrasting substantially higher frequencies in Asian versus Caucasian populations.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII)</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_population_ethnicity</strong></td>
                            <td>Asian; Caucasian</td>
                        </tr>
                        <tr>
                            <td><strong>study_population_location</strong></td>
                            <td>Global / multiple studies (by ethnicity)</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_frequency</strong></td>
                            <td>Asian: 40%–50%; Caucasian: 10%–30% (overall activating EGFR mutations)</td>
                        </tr>
                        <tr>
                            <td><strong>specific_mutation_types</strong></td>
                            <td>General activating EGFR mutations (exons 18-21; classical: exon 19 deletions and exon 21 L858R)</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_with_other_ethnicities</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>comparative_frequency_data</strong></td>
                            <td>Asian: 40%–50% overall EGFR mutation prevalence; Caucasian: 10%–30% overall EGFR mutation prevalence</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_status_correlation</strong></td>
                            <td>Not specified for this particular aggregated prevalence statement (but elsewhere EGFR mutations are associated with never-smokers).</td>
                        </tr>
                        <tr>
                            <td><strong>gender_correlation</strong></td>
                            <td>Not specified for this aggregated prevalence statement (but elsewhere EGFR mutations are more frequent in females).</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_genetic</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_environmental</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_lifestyle</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_other</strong></td>
                            <td>No mechanistic explanation provided here in this review; prevalence range is cited from a systematic review (mutMapII).</td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_histology</strong></td>
                            <td>Primarily NSCLC / adenocarcinoma (context of cited systematic review)</td>
                        </tr>
                        <tr>
                            <td><strong>response_to_egfr_inhibitors</strong></td>
                            <td>Classical EGFR mutations (exon 19 deletions, exon 21 L858R) are sensitive to first-, second-, and third-generation EGFR-TKIs; this statement is general and not ethnicity-specific in this paper.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Targeting EGFR Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer: Changes in Treatment Strategies are Coming', 'publication_date_yy_mm': '2024-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e340.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e340.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation prevalence in lung cancer across different ethnic populations, particularly comparing Asian and non-Asian populations, and any proposed explanations for ethnic differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>EGFR exon 20 insertion (ex20ins) share</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Prevalence of EGFR exon 20 insertion mutations among EGFR-positive NSCLC</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>The review states the proportion of exon 20 insertion mutations among all EGFR-mutated NSCLCs and notes epidemiologic associations (sex, ethnicity, smoking) reported in referenced studies.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_population_ethnicity</strong></td>
                            <td>mixed / various cohorts referenced (Asian-enriched in some reports)</td>
                        </tr>
                        <tr>
                            <td><strong>study_population_location</strong></td>
                            <td>multiple (datasets and studies from Asia, US, Europe cited in review)</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_frequency</strong></td>
                            <td>EGFR exon 20 insertions account for approximately 4%–12% of all EGFR-positive NSCLCs (review's summary range).</td>
                        </tr>
                        <tr>
                            <td><strong>specific_mutation_types</strong></td>
                            <td>EGFR exon 20 insertions (diverse subtypes within codons E762-C775); contrasted with classical exon 19 deletions and exon 21 L858R.</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_with_other_ethnicities</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>comparative_frequency_data</strong></td>
                            <td>The review states ex20ins are more common among Asian patients in cited data (see specific study-level entries); also reports that ex20ins are more frequent among women and never-smokers compared with EGFR wild-type or other mutation groups.</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_status_correlation</strong></td>
                            <td>Ex20ins are more common in never-smokers (examples in the review: 56% of ex20ins vs 20% of EGFR WT, P < 0.0001).</td>
                        </tr>
                        <tr>
                            <td><strong>gender_correlation</strong></td>
                            <td>Ex20ins are more common in women (example in the review: 47% of ex20ins vs 28% of EGFR WT, P = 0.003).</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_genetic</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_environmental</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_lifestyle</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_other</strong></td>
                            <td>The review highlights methodological/detection issues (PCR under-detection vs NGS) and unequal access to NGS across regions, which can produce apparent differences in observed prevalence between populations (detection bias / underdiagnosis).</td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_histology</strong></td>
                            <td>NSCLC (primarily lung adenocarcinoma in many cited datasets)</td>
                        </tr>
                        <tr>
                            <td><strong>response_to_egfr_inhibitors</strong></td>
                            <td>EGFR ex20ins mutations are generally insensitive to conventional EGFR-TKIs (first/second/third generation), leading to poorer prognosis compared with classical EGFR mutations; no ethnicity-specific response rates provided.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Targeting EGFR Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer: Changes in Treatment Strategies are Coming', 'publication_date_yy_mm': '2024-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e340.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e340.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation prevalence in lung cancer across different ethnic populations, particularly comparing Asian and non-Asian populations, and any proposed explanations for ethnic differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Qin2020 (Chinese dataset)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Variability of EGFR exon 20 insertions in 24 468 Chinese lung cancer patients and their divergent responses to EGFR inhibitors</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A large Chinese cohort study cited in the review reporting the frequency and subtype distribution of EGFR exon 20 insertions in 24,468 Chinese lung cancer patients (Table 2 entry in the review).</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Variability of EGFR exon 20 insertions in 24 468 Chinese lung cancer patients and their divergent responses to EGFR inhibitors</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_population_ethnicity</strong></td>
                            <td>Chinese / East Asian</td>
                        </tr>
                        <tr>
                            <td><strong>study_population_location</strong></td>
                            <td>China</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size</strong></td>
                            <td>24,468</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_frequency</strong></td>
                            <td>EGFR exon 20 insertion incidence reported as 2.24% (547/24,468) in this Chinese cohort (Table 2).</td>
                        </tr>
                        <tr>
                            <td><strong>specific_mutation_types</strong></td>
                            <td>Many subtypes reported; frequent subtypes listed in table include A767_V769dup (25.1%), S768_D770dup (17.6%), A763_Y764insFQEA (4.8%), H773_V774dup (4.6%), D770_N771insG (4.4%) among others (as reported in review's Table 2).</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_with_other_ethnicities</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>comparative_frequency_data</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>smoking_status_correlation</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>gender_correlation</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_genetic</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_environmental</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_lifestyle</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_other</strong></td>
                            <td>Provides empirical frequency in a large Chinese population; the review uses such datasets to illustrate geographic/ethnic variability but does not ascribe mechanistic causes.</td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_histology</strong></td>
                            <td>Lung cancer patients (context in cited title suggests broader lung cancer cohort; review focuses on NSCLC/adenocarcinoma relevance)</td>
                        </tr>
                        <tr>
                            <td><strong>response_to_egfr_inhibitors</strong></td>
                            <td>The cited study and review discuss divergent responses by subtype but do not provide ethnicity-stratified therapeutic-response rates here.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Targeting EGFR Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer: Changes in Treatment Strategies are Coming', 'publication_date_yy_mm': '2024-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e340.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e340.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation prevalence in lung cancer across different ethnic populations, particularly comparing Asian and non-Asian populations, and any proposed explanations for ethnic differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Leduc2017 (French IFCT)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A nationwide French study cited in the review reporting EGFR mutation characteristics and including an EGFR exon 20 insertion prevalence entry used in the review's Table 2.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_population_ethnicity</strong></td>
                            <td>French / European (Caucasian)</td>
                        </tr>
                        <tr>
                            <td><strong>study_population_location</strong></td>
                            <td>France</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size</strong></td>
                            <td>17,664</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_frequency</strong></td>
                            <td>EGFR exon 20 insertion incidence reported as 0.58% (102/17,664) in this cohort (Table 2 in the review).</td>
                        </tr>
                        <tr>
                            <td><strong>specific_mutation_types</strong></td>
                            <td>Table 2 lists >32 subtypes in this dataset; examples include N771_H773dup (7.84%), A767_V769dup (7.84%), S768_V769insIL (5.88%), S768_D770dup (5.88%) as reported in review's Table 2.</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_with_other_ethnicities</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>comparative_frequency_data</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>smoking_status_correlation</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>gender_correlation</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_genetic</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_environmental</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_lifestyle</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_other</strong></td>
                            <td>This European (French) dataset provides a lower observed incidence of ex20ins compared with the large Chinese dataset cited, illustrating geographic/ethnic variability; the review emphasizes detection methodology differences as a contributor to observed variability.</td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_histology</strong></td>
                            <td>NSCLC</td>
                        </tr>
                        <tr>
                            <td><strong>response_to_egfr_inhibitors</strong></td>
                            <td>Not ethnicity-stratified in the review summary; general statement that ex20ins have limited sensitivity to conventional EGFR-TKIs.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Targeting EGFR Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer: Changes in Treatment Strategies are Coming', 'publication_date_yy_mm': '2024-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e340.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e340.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation prevalence in lung cancer across different ethnic populations, particularly comparing Asian and non-Asian populations, and any proposed explanations for ethnic differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Oxnard2013 (small US cohort)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>EGFR exon 20 insertions in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>An earlier dataset (Oxnard 2013) cited in the review reporting ex20ins incidence and subtypes in a cohort used to illustrate heterogeneity and prevalence differences across studies.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>EGFR exon 20 insertions in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_population_ethnicity</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_population_location</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>sample_size</strong></td>
                            <td>1,086</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_frequency</strong></td>
                            <td>EGFR exon 20 insertion incidence reported as 2.49% (27/1,086) in this cohort (Table 2 in the review).</td>
                        </tr>
                        <tr>
                            <td><strong>specific_mutation_types</strong></td>
                            <td>Reported subtypes include V769_D770insASV (22.22%), H773insH (11.11%), A763_Y764insFQEA (11.11%), H773_V774insPH (7.41%), H773_V774insNPH (7.41%) (from Table 2).</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_with_other_ethnicities</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>comparative_frequency_data</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>smoking_status_correlation</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>gender_correlation</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_genetic</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_environmental</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_lifestyle</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_other</strong></td>
                            <td>Serves as an earlier reference point for ex20ins prevalence and subtype diversity; review highlights heterogeneity across datasets and the role of testing methods (PCR vs NGS) in detectability.</td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_histology</strong></td>
                            <td>Lung adenocarcinoma / NSCLC</td>
                        </tr>
                        <tr>
                            <td><strong>response_to_egfr_inhibitors</strong></td>
                            <td>Not stratified by ethnicity in the review; emphasis is that ex20ins are generally less sensitive to conventional EGFR-TKIs.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Targeting EGFR Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer: Changes in Treatment Strategies are Coming', 'publication_date_yy_mm': '2024-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII) <em>(Rating: 2)</em></li>
                <li>Variability of EGFR exon 20 insertions in 24 468 Chinese lung cancer patients and their divergent responses to EGFR inhibitors <em>(Rating: 2)</em></li>
                <li>Diverse EGFR exon 20 insertions and Co-occurring molecular alterations identified by comprehensive genomic profiling of NSCLC <em>(Rating: 2)</em></li>
                <li>EGFR exon 20 insertions in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics <em>(Rating: 2)</em></li>
                <li>EGFR exon 20 insertion in lung adenocarcinomas among Hispanics (geno1.2-CLICaP) <em>(Rating: 1)</em></li>
                <li>Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program <em>(Rating: 2)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>